Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

MLA

Nischal Ranganath, et al. “Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.” Clinical Infectious Diseases, vol. 76, June 2022, pp. e537–39. EBSCOhost, https://doi.org/10.1093/cid/ciac481.

APA

Nischal Ranganath, John C O’Horo, Douglas W Challener, Sidna M Tulledge-Scheitel, Marsha L Pike, Michael O’Brien, Raymund R Razonable, & Aditya Shah. (2022). Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases, 76, e537–e539. https://doi.org/10.1093/cid/ciac481

Chicago

Nischal Ranganath, John C O’Horo, Douglas W Challener, Sidna M Tulledge-Scheitel, Marsha L Pike, Michael O’Brien, Raymund R Razonable, and Aditya Shah. 2022. “Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.” Clinical Infectious Diseases 76 (June): e537–39. doi:10.1093/cid/ciac481.